| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/05/2009 | US20090062302 Jak2 Tyrosine Kinase Inhibition |
| 03/05/2009 | US20090062294 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| 03/05/2009 | US20090062288 Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| 03/05/2009 | US20090062286 Crystal Structure of SMYD3 Protein |
| 03/05/2009 | US20090062281 such as 7-(2-[1,4']Bipiperidinyl-1'-yl-ethoxy)-6-methoxy-4-(4-phenoxy-phenylamino)-quinoline-3-carbonitrile, useful in the prevention of diseases associated with the Ras/Raf/MEK signaling cascade in a mammals, such as tumors, cancer, strokes, osteoporosis, arthritis and inflammatory diseases |
| 03/05/2009 | US20090062272 Imidazoquinolinyl sulfonamides |
| 03/05/2009 | US20090062268 Novel inhibitors of poly(adp-ribose)polymerase (parp) |
| 03/05/2009 | US20090062267 L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS |
| 03/05/2009 | US20090062243 Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof |
| 03/05/2009 | US20090062230 Novel cationic 17 alpha-substituted-estradiol derivatives useful as anti-cancer agent |
| 03/05/2009 | US20090062227 Methods and compositions for inducing apoptosis by stimulating er stress |
| 03/05/2009 | US20090062226 Method and Compositions for Inhibiting MAGE Protein Interaction With KAP-1 |
| 03/05/2009 | US20090062222 Methods for Sensitizing Cancer Cells to Inhibitors |
| 03/05/2009 | US20090062206 Urodilatin Cancer Treatment |
| 03/05/2009 | US20090062196 Compositions and methods of treating cancer |
| 03/05/2009 | US20090062133 Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer |
| 03/05/2009 | US20090061022 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 03/05/2009 | US20090061010 Cancer cell targeting using nanoparticles |
| 03/05/2009 | US20090060968 Inhibitors of phosphatases |
| 03/05/2009 | US20090060953 Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| 03/05/2009 | US20090060946 Activation of antigen-specific T cells by virus/antigen-treated dendritic cells |
| 03/05/2009 | US20090060938 Polyvalent Conjugate Vaccine for Cancer |
| 03/05/2009 | US20090060937 Immunostimulatory oligonucleotides and uses thereof |
| 03/05/2009 | US20090060936 Ii-Key/Her-2/neu hybrid cancer vaccine |
| 03/05/2009 | US20090060931 Pharmaceutical composition for treating or preventing ovarian cancer |
| 03/05/2009 | US20090060929 Gene therapy and vaccination; non-viral transfection complex of a nucleic acid, optionally, a lipid,a polycationic nucleic acid-binding component, and a cell surface receptor binding peptide of given sequence |
| 03/05/2009 | US20090060928 Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
| 03/05/2009 | US20090060926 Medicine for treatment of carcinoma |
| 03/05/2009 | US20090060925 Rage Fusion Proteins and Methods of Use |
| 03/05/2009 | US20090060912 Small molecule pi 3-kinase inhibitors and methods of their use |
| 03/05/2009 | US20090060911 Enhancement of antibody-mediated immune responses |
| 03/05/2009 | US20090060910 Covalent diabodies and uses thereof |
| 03/05/2009 | US20090060909 Antibody antagonists of ve-cadherin without adverse effects on vascular permeability |
| 03/05/2009 | US20090060907 Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3 |
| 03/05/2009 | US20090060900 Methods for Screening Compounds That Modulate Lipid Metabolism |
| 03/05/2009 | US20090060889 Ii-RNAi involved Ii suppression in cancer immunotherapy |
| 03/05/2009 | US20090060873 Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris |
| 03/05/2009 | US20090060870 for treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as human papilloma virus-induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias; measuring or detecting the presence of a CD4+ type 1 T helper (Th1) cell response against an HPV |
| 03/05/2009 | US20090060865 Mammalian receptor proteins; related reagents and methods |
| 03/05/2009 | US20090060864 administering an antitumor agent containing a combination of an alpha v beta 3 angiogenisis antagonist and an anti-tumor immunotherapeutic agent, which is a fusion protein of a cytokine IL-2 and an Ig heavy chain that immunoreacts with a tumor associated antigen target; drug target |
| 03/05/2009 | US20090060842 Method for diagnosis and treatment of prostatitis |
| 03/05/2009 | US20090060839 Gold Nanoparticle Conjugates and Uses Thereof |
| 03/05/2009 | DE102007041832A1 Arzneimittel und Verfahren zur Behandlung von Prostatakrebs Pharmaceutical compositions and methods for treating prostate cancer |
| 03/05/2009 | DE102007041116A1 1,3-Dihydro-isoindolderivate 1,3-dihydro-isoindolderivate |
| 03/05/2009 | DE102007041115A1 Thiadiazinonderivate Thiadiazinonderivate |
| 03/05/2009 | CA2844647A1 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| 03/05/2009 | CA2698146A1 Anti-epha2 antibody |
| 03/05/2009 | CA2698094A1 Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods |
| 03/05/2009 | CA2698071A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/05/2009 | CA2698018A1 Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| 03/05/2009 | CA2697949A1 Cancer imaging and treatment |
| 03/05/2009 | CA2697795A1 Inhibitors of protein tyrosine kinase activity |
| 03/05/2009 | CA2697663A1 Substituted pyrazole derivative |
| 03/05/2009 | CA2697529A1 Receptor-targeting reagents |
| 03/05/2009 | CA2697517A1 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 03/05/2009 | CA2697513A1 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
| 03/05/2009 | CA2697512A1 Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
| 03/05/2009 | CA2697501A1 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent |
| 03/05/2009 | CA2697382A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| 03/05/2009 | CA2697376A1 Liquid formulation of g-csf |
| 03/05/2009 | CA2697167A1 Benzimidazole derivatives used as fxr agonists |
| 03/05/2009 | CA2697070A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 03/05/2009 | CA2696799A1 Piperidine derivative |
| 03/05/2009 | CA2696767A1 Heterocyclic amides useful for the treatment of cancer and psoriasis |
| 03/05/2009 | CA2696622A1 Compositions for the treatment of neoplastic diseases |
| 03/04/2009 | EP2031076A1 Novel compositions and methods for cancer |
| 03/04/2009 | EP2031056A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 03/04/2009 | EP2030978A1 Phosphine transition metal complex, method for producing the same and antitumor agent |
| 03/04/2009 | EP2030634A1 Medicament for and method of treatment of prostate cancer |
| 03/04/2009 | EP2030618A2 Combinations comprising epothilones and anti-metabolites |
| 03/04/2009 | EP2029627A2 Hepatocyte growth factor (hgf) binding proteins |
| 03/04/2009 | EP2029618A2 Agents, methods and uses |
| 03/04/2009 | EP2029608A1 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use |
| 03/04/2009 | EP2029605A1 Imidazopyrazines as protein kinase inhibitors |
| 03/04/2009 | EP2029600A1 Substituted pteridines substituted with a four-membered heterocycle |
| 03/04/2009 | EP2029597A2 Purine analogs |
| 03/04/2009 | EP2029592A1 Pharmaceutical compounds |
| 03/04/2009 | EP2029584A2 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use |
| 03/04/2009 | EP2029580A1 Novel indol-pyrrol derivatives for the treatment of proliferative and inflammatory diseases |
| 03/04/2009 | EP2029578A1 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
| 03/04/2009 | EP2029568A1 Flavonoid dimers and methods of making and using such |
| 03/04/2009 | EP2029566A2 Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| 03/04/2009 | EP2029555A2 Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same |
| 03/04/2009 | EP2029552A1 Sulfimides as protein kinase inhibitors |
| 03/04/2009 | EP2029535A1 Isoindole derivatives useful for treating pain, gastrointestinal diseases and cancer |
| 03/04/2009 | EP2029517A2 Antiproliferative compounds, compositions and methods of use |
| 03/04/2009 | EP2029184A1 Injectable fibrin composition for bone augmentation |
| 03/04/2009 | EP2029173A2 Fc riib-specific antibodies and methods of use thereof |
| 03/04/2009 | EP2029158A1 Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| 03/04/2009 | EP2029154A2 Treatment of melanoma |
| 03/04/2009 | EP2029147A1 Methods for treating cancer |
| 03/04/2009 | EP2029145A2 Pyrrolopyrimidine compounds and their uses |
| 03/04/2009 | EP2029144A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
| 03/04/2009 | EP2029125A2 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown |
| 03/04/2009 | EP1765351B1 Protein kinase inhibitors |
| 03/04/2009 | EP1708693B1 Pharmaceutical compositions containing paltinum complexes with secondary xanthates and therapeutic uses thereof |
| 03/04/2009 | EP1696913B1 Pharmaceutical composition of vinflunine for parenteral administration, preparation method thereof and use of same |
| 03/04/2009 | EP1663236B1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate |
| 03/04/2009 | EP1575579B1 Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 03/04/2009 | EP1551812B1 Mitotic kinesin inhibitors |